A detailed history of Wipfli Financial Advisors Llc, transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Wipfli Financial Advisors Llc, holds 139 shares of RLMD stock, worth $418. This represents 0.0% of its overall portfolio holdings.

Number of Shares
139
Holding current value
$418
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 26, 2022

BUY
$18.3 - $37.02 $2,543 - $5,145
139 New
139 $5,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $86.1M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Wipfli Financial Advisors Llc, Portfolio

Follow Wipfli Financial Advisors Llc, and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wipfli Financial Advisors Llc,, based on Form 13F filings with the SEC.

News

Stay updated on Wipfli Financial Advisors Llc, with notifications on news.